Epitide

Epitide, commercially known as MATRIXYL synthe'6 (Palmitoyl Tripeptide-38), is a matrikine-mimetic lipopeptide developed by Sederma. The sequence Pal-Lys-Met(O2)-Lys was inspired by a natural tripeptide found in collagen VI and laminin. It stimulates synthesis of six key extracellular matrix components simultaneously, earning its name. It is used in premium anti-aging skincare formulations targeting fine lines, deep wrinkles, and loss of skin volume, and also finds application in lip-plumping products under the Volulip trade name.

Palmitoyl Tripeptide-38 acts as a matrikine — a bioactive peptide fragment derived from ECM proteins — that signals fibroblasts and keratinocytes to upregulate production of six dermal matrix constituents: collagen I, collagen III, collagen IV, fibronectin, hyaluronic acid, and laminin-5. It modulates MMP activity to reduce collagen degradation while simultaneously driving new ECM synthesis through activation of TGF-β and integrin-mediated pathways. The palmitoyl lipid tail enhances skin penetration through the lipid-rich stratum corneum and tethers the peptide to cell membranes, increasing dwell time at the target receptor site. This broad-spectrum ECM stimulation results in improved dermal thickness, elasticity, and hydration.

Sederma-sponsored clinical studies report statistically significant reductions in wrinkle volume, improvements in skin tone uniformity, and increased skin density after 28–56 days of twice-daily topical use. In vitro studies on fibroblast and keratinocyte cultures confirm upregulation of all six ECM targets at the mRNA and protein level. A 2025 PMC review of bioactive oligopeptides in skin regeneration cites Palmitoyl Tripeptide-38 as among the most comprehensively studied matrikine-class cosmetic actives. Independent peer-reviewed clinical validation remains limited as of 2026.

Peptides commonly paired with Epitide for synergistic effects.